Beta Drugs Limited has informed the Exchange about approval of Listing of equity shares of Beta Drugs Limited on Capital Market Segment (Main Board) pursuant to Migration from SME Emerge platform (NSE).
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Beta Drugs Limited has received approval for listing its equity shares on the Capital Market Segment (Main Board) of NSE. This follows a migration from the SME Emerge platform where the stock was previously listed. The company has met the eligibility criteria required for shifting to the main board. This marks a transition from the small and medium enterprise segment to the broader capital market segment.
Main board listing typically improves stock visibility, attracts institutional investors, and may boost trading liquidity. For existing shareholders, this migration is generally seen as a positive milestone reflecting growth and improved eligibility.